RT Book, Section
A1 Lewis, William
A1 Currie, Peter F.
A2 Fuster, Valentin
A2 Harrington, Robert A.
A2 Narula, Jagat
A2 Eapen, Zubin J.
SR Print(0)
ID 1191188518
T1 HIV/AIDS AND THE CARDIOVASCULAR SYSTEM
T2 Hurst's The Heart, 14e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071843249
LK accesscardiology.mhmedical.com/content.aspx?aid=1191188518
RD 2024/04/19
AB SummaryThis  chapter  discusses  the  cardiovascular  effects  of  human  immunodeficiency  virus  (HIV)/acquired  immunodeficiency  syndrome  (AIDS)  and  the  adverse  cardiovascular  effects  of  therapy.  Prior  to  highly  active  antiretroviral  therapy  (HAART),  >6%  of  HIV/AIDS  patients  had  cardiovascular  diseases,  but  many  of  these  conditions  were  mild.  Since  then,  with  environmental  stresses,  the  toxicities  associated  with  contemporary  therapies,  and  the  increased  life  span  that  has  resulted  from  the  efficacy  of  contemporary  therapies,  the  spectrum  of  cardiovascular  disease  experienced  by  HIV/AIDS  patients  has  changed  (see  accompanying  Hurst’s  Central  Illustration).  Nonbacterial  thrombotic  endocarditis  is  now  rarely  reported  in  patients  with  HIV/AIDS,  but  pericarditis  and  myocarditis  remain  prevalent  in  the  developing  world.  Both  HIV-1  infection  itself  and  HAART  may  have  a  negative  impact  on  myocardial  function  and  be  involved  in  the  development  of  HIV/AIDS  cardiomyopathy.  In  developed  countries,  premature  coronary  artery  disease,  metabolic  syndrome,  and  other  manifestations  of  atherosclerosis  are  emerging  as  key  cardiovascular  disorders  in  the  HIV/AIDS  patient  population.  HIV/AIDS  patients  should  be  assessed  for  traditional  cardiovascular  risk  factors  that  are  prevalent  in  this  population  irrespective  of  therapy.  Notably,  possible  cardiovascular  drug  interactions  with  HIV/AIDS  therapies  have  been  reported.